ABK-KRAS-1
/ Abbisko
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
Discovery and characterization of a highly potent and orally available small-molecule inhibitor for diverse KRAS mutations
(AACR 2025)
- "In vivo efficacy studies further demonstrated robust anti-tumor activity of ABK-KRAS-1 in multiple xenograft models dependent on various KRAS mutations. Preclinical DMPK analyses confirmed excellent bioavailability across multiple animal species.Collectively, the superior preclinical profile of ABK-KRAS-1 supports its advancement into preclinical development."
Late-breaking abstract • Colorectal Cancer • Lung Cancer • Oncology • Solid Tumor • KRAS
1 to 1
Of
1
Go to page
1